Gri bio presents data supporting innovative pipeline of nkt cell modulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases

Data presented at the 7 th annual antifibrotic drug development (afdd) summit company's lead program, gri-0621, has demonstrated ability to inhibit the activity of type i invariant nkt (inkt) cells early in the inflammatory cascade to prevent cytokine release, cellular infiltration, and interrupts disease progression at the source daily oral administration of gri-0621 (a human equivalent dose) leads to reduced lung damage and a significant reduction in bleomycin-induced lung fibrosis la jolla, ca, oct. 31, 2023 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (“nkt”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the presentation of data supporting its novel approach to inflammatory diseases at the 7th annual antifibrotic drug development (afdd) summit held october 24-26, 2023 in boston, ma. as part of the afdd summit, vipin kumar, phd, chief scientific officer of gri bio gave an oral presentation titled, “exploration of nkt cell activation as an immune biomarker for progression of fibrosis,” and participated in a panel discussion titled, reviewing biomarkers discussed in the context of fibrosis & oncology, which discussed the promising new avenues for evaluating fibrosis staging in vivo, in vitro and in patient; review the advantages and pitfalls of fluid markers vs imaging for fibrosis diagnostics; and illuminate similarities and differences in biomarkers across fibrotic disease and tumor fibrosis.
GRI Ratings Summary
GRI Quant Ranking